Literature DB >> 18074122

The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.

Beatriz Goni-Allo1, Brian O Mathúna, Mireia Segura, Elena Puerta, Berta Lasheras, Rafael de la Torre, Norberto Aguirre.   

Abstract

RATIONALE: A close relationship appears to exist between 3,4-methylenedioxymethamphetamine (MDMA)-induced changes in core body temperature and long-term serotonin (5-HT) loss.
OBJECTIVE: We investigated whether changes in core body temperature affect MDMA metabolism.
MATERIALS AND METHODS: Male Wistar rats were treated with MDMA at ambient temperatures of 15, 21.5, or 30 degrees C to prevent or exacerbate MDMA-induced hyperthermia. Plasma concentrations of MDMA and its main metabolites were determined for 6 h. Seven days later, animals were killed and brain indole content was measured.
RESULTS: The administration of MDMA at 15 degrees C blocked the hyperthermic response and long-term 5-HT depletion found in rats treated at 21.5 degrees C. At 15 degrees C, plasma concentrations of MDMA were significantly increased, whereas those of three of its main metabolites were reduced when compared to rats treated at 21.5 degrees C. By contrast, hyperthermia and indole deficits were exacerbated in rats treated at 30 degrees C. Noteworthy, plasma concentrations of MDMA metabolites were greatly enhanced in these animals. Instrastriatal perfusion of MDMA (100 microM for 5 h at 21 degrees C) did not potentiate the long-term depletion of 5-HT after systemic MDMA. Furthermore, interfering in MDMA metabolism using the catechol-O-methyltransferase inhibitor entacapone potentiated the neurotoxicity of MDMA, indicating that metabolites that are substrates for this enzyme may contribute to neurotoxicity.
CONCLUSIONS: This is the first report showing a direct relationship between core body temperature and MDMA metabolism. This finding has implications on both the temperature dependence of the mechanism of MDMA neurotoxicity and human use, as hyperthermia is often associated with MDMA use in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18074122     DOI: 10.1007/s00213-007-1027-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  54 in total

1.  3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose.

Authors:  B Esteban; E O'Shea; J Camarero; V Sanchez; A R Green; M I Colado
Journal:  Psychopharmacology (Berl)       Date:  2001-03       Impact factor: 4.530

2.  Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink.

Authors:  A Hem; A J Smith; P Solberg
Journal:  Lab Anim       Date:  1998-10       Impact factor: 2.471

Review 3.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

4.  Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.

Authors:  W L Nixdorf; K B Burrows; G A Gudelsky; B K Yamamoto
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

5.  Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.

Authors:  F Bai; D C Jones; S S Lau; T J Monks
Journal:  Chem Res Toxicol       Date:  2001-07       Impact factor: 3.739

6.  Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.

Authors:  Douglas C Jones; Christine Duvauchelle; Aiko Ikegami; Christopher M Olsen; Serrine S Lau; Rafael de la Torre; Terrence J Monks
Journal:  J Pharmacol Exp Ther       Date:  2005-01-05       Impact factor: 4.030

7.  Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats.

Authors:  Beatriz Goñi-Allo; Elena Puerta; Isabel Hervias; Richard Di Palma; Maria Ramos; Berta Lasheras; Norberto Aguirre
Journal:  Eur J Pharmacol       Date:  2007-02-01       Impact factor: 4.432

8.  Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  T Taraska; K T Finnegan
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

9.  Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy).

Authors:  Jon E Sprague; Matthew L Banks; Valerie J Cook; Edward M Mills
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

10.  Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.

Authors:  Veronica Sanchez; Esther O'shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado; A Richard Green
Journal:  J Psychopharmacol       Date:  2004-09       Impact factor: 4.153

View more
  18 in total

1.  Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Authors:  Samanta Yubero-Lahoz; Mario A Ayestas; Bruce E Blough; John S Partilla; Richard B Rothman; Rafael de la Torre; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2011-11-03       Impact factor: 4.432

2.  Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors:  Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

3.  MDMA: on the translation from rodent to human dosing.

Authors:  A Richard Green; Johan Gabrielsson; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

4.  Comment on the letter by Green, Gabrielsson, Marsden, and Fone, MDMA: on the translation from rodent to human dosing.

Authors:  Rafael de la Torre; Elena Puerta; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

Review 5.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 6.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

7.  THC Prevents MDMA Neurotoxicity in Mice.

Authors:  Clara Touriño; Andreas Zimmer; Olga Valverde
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

8.  Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain.

Authors:  Amit Khairnar; Antonio Plumitallo; Lucia Frau; Nicoletta Schintu; Micaela Morelli
Journal:  Neurotox Res       Date:  2009-10-31       Impact factor: 3.911

9.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

10.  Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile.

Authors:  Melanie Mueller; Concepcion Maldonado-Adrian; Jie Yuan; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2012-12-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.